Oxford Biomedica Plc And Arius Research Inc. Sign Collaborative Programme In Tumour ImmunotherapyJuly 25, 2002Oxford, United Kingdom and Toronto, Canada - 25 July 2002. Oxford BioMedica plc (LSE:OXB) ("BioMedica") and ARIUS Research Inc. ("ARIUS) of Canada announced today a research and development collaboration to search for targets and develop novel products to treat cancer. Under the collaboration ARIUS will supply BioMedica with a range of 50 functional anti-tumour antibodies that it has identified using a unique novel approach. BioMedica will characterise the antibodies and identify the cognate antigens by employing a range of proprietary technologies from its gene discovery and immunotherapy programmes. The antigens and antibodies will be developed for use in immunotherapeutic approaches to the treatment of cancer. New products, such as vaccines or therapeutic antibodies, will be developed by the two companies or in conjunction with pharmaceutical partners. The appetite within the pharmaceutical industry for cancer therapies that make use of tumour specific antibodies or vaccines is increasing substantially. It has been estimated that the therapeutic antibody market alone will have grown to $4 billion by the end of 2002 and is set to rise steadily over the next 10 years. BioMedica is already a significant player in this field with its $24 million antibody deal with Wyeth and its very successful clinical trial results with the Company's proprietary therapeutic vaccine TroVax®. BioMedica has both the technical skills to develop these products and the business development experience to market them to larger pharmaceutical companies. If successful, TroVax® could reach the market in 4-5 years with sales exceeding $1 billion. Similarly, the Wyeth collaboration could yield a product of similar significance within a comparable time frame. The new collaboration between BioMedica and ARIUS is designed to provide a pipeline of cancer immunotherapy products that will be marketed jointly to the industry once proof of principle is established. The first output from the collaboration is expected within a year. Commenting on the collaboration, BioMedica's chief executive, Prof. Alan Kingsman said: Commenting on the collaboration ARIUS`s chief executive, David Young said: | |||||||||||||||||||||
|
Related Cancer Current Events and Cancer News Articles Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene. International study supports new standard of treatment for women with advanced ovarian cancer Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. Researchers identify cell group key to Lyme disease arthritis A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease. Researchers Discover New Enzyme in Cancer Growth While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body. Angled gantry technique reduced breast radiation exposure by 50 percent A novel angled gantry approach to coronary CT angiography reduced radiation exposure to the breast by more than 50%, according to Thomas Jefferson University researchers. HER2 levels may aid in treatment selection for metastatic breast cancer Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. Drop in cancer deaths tied primarily to gains in behavior and screening Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. Plants display 'molecular amnesia' Plant researchers from McGill University and the University of California, Berkeley, have announced a major breakthrough in a developmental process called epigenetics. They have demonstrated for the first time the reversal of what is called epigenetic silencing in plants. New breast imaging technology targets hard-to-detect cancers Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). Dancing atoms now understood In developing a model to explain the motion of atoms in a magnetic field, scientists have overcome a decades-old obstacle to understanding a key component of magnetic resonance. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||